Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Effect of Cryotherapy vs Loop Electrosurgical Excision Procedure on Cervical Disease Recurrence Among Women With HIV and High-Grade Cervical Lesions in Kenya: A Randomized Clinical Trial.

Greene SA, De Vuyst H, John-Stewart GC, Richardson BA, McGrath CJ, Marson KG, Trinh TT, Yatich N, Kiptinness C, Cagle A, Nyongesa-Malava E, Sakr SR, Mugo NR, Chung MH.

JAMA. 2019 Oct 22;322(16):1570-1579. doi: 10.1001/jama.2019.14969.

PMID:
31638680
2.

Development and Validation of the First Point-of-Care Assay to Objectively Monitor Adherence to HIV Treatment and Prevention in Real-Time in Routine Settings.

Gandhi M, Wang G, King R, Rodrigues WC, Vincent M, Glidden DV, Cressey TR, Bacchetti P, Spinellii MA, Okochi H, Siriprakaisil O, Klinbuayaem V, Mugo NR, Ngure K, Drain PK, Baeten JM.

AIDS. 2019 Oct 11. doi: 10.1097/QAD.0000000000002395. [Epub ahead of print]

PMID:
31634188
3.

Global implementation of PrEP for HIV prevention: setting expectations for impact.

Pyra MN, Haberer JE, Hasen N, Reed J, Mugo NR, Baeten JM.

J Int AIDS Soc. 2019 Aug;22(8):e25370. doi: 10.1002/jia2.25370.

4.

Integrating PrEP into HIV care clinics could improve partner testing services and reinforce mutual support among couples: provider views from a PrEP implementation project in Kenya.

Odoyo JB, Morton JF, Ngure K, O'Malley G, Mugwanya KK, Irungu E, Awuor M, Dolla A, Ongolly F, Bukusi EA, Mugo NR, Baeten JM; Partners Scale-Up Project Team.

J Int AIDS Soc. 2019 Jul;22 Suppl 3:e25303. doi: 10.1002/jia2.25303.

5.

HIV-1 self-testing to improve the efficiency of pre-exposure prophylaxis delivery: a randomized trial in Kenya.

Ortblad KF, Kearney JE, Mugwanya K, Irungu EM, Haberer JE, Barnabas RV, Donnell D, Mugo NR, Baeten JM, Ngure K.

Trials. 2019 Jul 4;20(1):396. doi: 10.1186/s13063-019-3521-2.

6.

Estimating the costs of HIV clinic integrated versus non-integrated treatment of pre-cancerous cervical lesions and costs of cervical cancer treatment in Kenya.

Vodicka EL, Chung MH, Zimmermann MR, Kosgei RJ, Lee F, Mugo NR, Okech TC, Sakr SR, Stergachis A, Garrison LP Jr, Babigumira JB.

PLoS One. 2019 Jun 6;14(6):e0217331. doi: 10.1371/journal.pone.0217331. eCollection 2019.

7.

Tenofovir-Diphosphate as a Marker of HIV Pre-exposure Prophylaxis Use Among East African Men and Women.

Pyra M, Anderson P, Haberer JE, Heffron R, Celum C, Asiimwe S, Katabira E, Mugo NR, Bukusi EA, Baeten JM.

Front Pharmacol. 2019 Apr 17;10:401. doi: 10.3389/fphar.2019.00401. eCollection 2019.

8.

Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence.

Gandhi M, Bacchetti P, Rodrigues WC, Spinelli M, Koss CA, Drain PK, Baeten JM, Mugo NR, Ngure K, Benet LZ, Okochi H, Wang G, Vincent M.

EClinicalMedicine. 2018 Aug-Sep;2-3:22-28. doi: 10.1016/j.eclinm.2018.08.004. Epub 2018 Aug 31.

9.

Correction: Whole genome sequencing of extreme phenotypes identifies variants in CD101 and UBE2V1 associated with increased risk of sexually acquired HIV-1.

Mackelprang RD, Bamshad MJ, Chong JX, Hou X, Buckingham KJ, Shively K, deBruyn G, Mugo NR, Mullins JI, McElrath MJ, Baeten JM, Celum C, Emond MJ, Lingappa JR; Partners in Prevention HSV/HIV Transmission Study and the Partners PrEP Study Teams.

PLoS Pathog. 2019 Feb 11;15(2):e1007588. doi: 10.1371/journal.ppat.1007588. eCollection 2019 Feb.

10.

Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status.

Mugo NR, Eckert L, Magaret AS, Cheng A, Mwaniki L, Ngure K, Celum C, Baeten JM, Galloway DA, Wamalwa D, Wald A.

Vaccine. 2018 Nov 12;36(46):7025-7032. doi: 10.1016/j.vaccine.2018.09.059. Epub 2018 Oct 5.

PMID:
30297124
11.

ScaleĀ up of PrEP integrated in public health HIV care clinics: a protocol for a stepped-wedge cluster-randomized rollout in Kenya.

Mugwanya KK, Irungu E, Bukusi E, Mugo NR, Odoyo J, Wamoni E, Ngure K, Morton JF, Peebles K, Masyuko S, Barnabee G, Donnell D, Barnabas R, Haberer J, O'Malley G, Baeten JM; Partners Scale Up Team.

Implement Sci. 2018 Sep 4;13(1):118. doi: 10.1186/s13012-018-0809-7.

12.

Effect of Depression on Adherence to Oral PrEP Among Men and Women in East Africa.

Velloza J, Baeten JM, Haberer J, Ngure K, Irungu E, Mugo NR, Celum C, Heffron R; Partners Demonstration Project Team.

J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):330-338. doi: 10.1097/QAI.0000000000001821.

13.

Patterns of Oral PrEP Adherence and HIV Risk Among Eastern African Women in HIV Serodiscordant Partnerships.

Pyra M, Brown ER, Haberer JE, Heffron R, Celum C, Bukusi EA, Asiimwe S, Katabira E, Mugo NR, Baeten JM; Partners Demonstration Project Team.

AIDS Behav. 2018 Nov;22(11):3718-3725. doi: 10.1007/s10461-018-2221-3.

PMID:
30006791
14.

Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.

Pyra M, Anderson PL, Hendrix CW, Heffron R, Mugwanya K, Haberer JE, Thomas KK, Celum C, Donnell D, Marzinke MA, Bukusi EA, Mugo NR, Asiimwe S, Katabira E, Baeten JM; Partners Demonstration Study Team.

AIDS. 2018 Aug 24;32(13):1891-1898. doi: 10.1097/QAD.0000000000001922.

15.

Epstein-Barr Virus, High-Risk Human Papillomavirus and Abnormal Cervical Cytology in a Prospective Cohort of African Female Sex Workers.

Cameron JE, Rositch AF, Vielot NA, Mugo NR, Kwatampora JKL, Waweru W, Gilliland AE, Hagensee ME, Smith JS.

Sex Transm Dis. 2018 Oct;45(10):666-672. doi: 10.1097/OLQ.0000000000000857.

16.

Concordance of self-reported hormonal contraceptive use and presence of exogenous hormones in serum among African women.

Pyra M, Lingappa JR, Heffron R, Erikson DW, Blue SW, Patel RC, Nanda K, Rees H, Mugo NR, Davis NL, Kourtis AP, Baeten JM; Partners in Prevention HSV/HIV Transmission Study and Partners PrEP Study Teams.

Contraception. 2018 Apr;97(4):357-362. doi: 10.1016/j.contraception.2018.01.011. Epub 2018 Feb 17.

17.

Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study.

McClelland RS, Lingappa JR, Srinivasan S, Kinuthia J, John-Stewart GC, Jaoko W, Richardson BA, Yuhas K, Fiedler TL, Mandaliya KN, Munch MM, Mugo NR, Cohen CR, Baeten JM, Celum C, Overbaugh J, Fredricks DN.

Lancet Infect Dis. 2018 May;18(5):554-564. doi: 10.1016/S1473-3099(18)30058-6. Epub 2018 Jan 26.

18.

Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa.

Heffron R, Ngure K, Odoyo J, Bulya N, Tindimwebwa E, Hong T, Kidoguchi L, Donnell D, Mugo NR, Bukusi EA, Katabira E, Asiimwe S, Morton J, Morrison S, Haugen H, Mujugira A, Haberer JE, Ware NC, Wyatt MA, Marzinke MA, Frenkel LM, Celum C, Baeten JM; Partners Demonstration Project Team.

Version 2. Gates Open Res. 2018 Jan 30 [revised 2018 Jan 1];1:3. doi: 10.12688/gatesopenres.12752.2. eCollection 2017.

19.

The role of male partners in women's participation in research during pregnancy: a case study from the partners demonstration project.

Ngure K, Trinidad SB, Beima-Sofie K, Baeten JM, Mugo NR, Bukusi EA, Heffron R, John-Stewart G, Kelley MC.

Reprod Health. 2017 Dec 14;14(Suppl 3):160. doi: 10.1186/s12978-017-0424-0.

20.

Increased Cervical Human Immunodeficiency Virus (HIV) RNA Shedding Among HIV-Infected Women Randomized to Loop Electrosurgical Excision Procedure Compared to Cryotherapy for Cervical Intraepithelial Neoplasia 2/3.

Greene SA, McGrath CJ, Lehman DA, Marson KG, Trinh TT, Yatich N, Nyongesa-Malava E, Kiptinness C, Richardson BA, John-Stewart GC, De Vuyst H, Sakr SR, Mugo NR, Chung MH.

Clin Infect Dis. 2018 May 17;66(11):1778-1784. doi: 10.1093/cid/cix1096.

21.

Brief Report: Frequency of Monitoring Kidney Function in HIV-Uninfected Persons Using Daily Oral Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis.

Mugwanya KK, Baeten JM, Wyatt C, Mugo NR, Celum CL, Ronald A, Kiarie J, Katabira E, Heffron R; Partners PrEP Study and Partners Demonstration Project Teams.

J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):206-211. doi: 10.1097/QAI.0000000000001575.

22.

Whole genome sequencing of extreme phenotypes identifies variants in CD101 and UBE2V1 associated with increased risk of sexually acquired HIV-1.

Mackelprang RD, Bamshad MJ, Chong JX, Hou X, Buckingham KJ, Shively K, deBruyn G, Mugo NR, Mullins JI, McElrath MJ, Baeten JM, Celum C, Emond MJ, Lingappa JR; Partners in Prevention HSV/HIV Transmission Study and the Partners PrEP Study Teams.

PLoS Pathog. 2017 Nov 6;13(11):e1006703. doi: 10.1371/journal.ppat.1006703. eCollection 2017 Nov. Erratum in: PLoS Pathog. 2019 Feb 11;15(2):e1007588.

23.

Role of p16 testing in cervical cancer screening among HIV-infected women.

McGrath CJ, Garcia R, Trinh TT, Richardson BA, John-Stewart GC, Nyongesa-Malava E, Mugo NR, Glynn EH, Sakr SR, De Vuyst H, Chung MH.

PLoS One. 2017 Oct 12;12(10):e0185597. doi: 10.1371/journal.pone.0185597. eCollection 2017.

24.

Brief Report: PrEP Use During Periods of HIV Risk Among East African Women in Serodiscordant Relationships.

Pyra M, Haberer JE, Heffron R, Kidoguchi L, Brown ER, Bukusi EA, Asiimwe S, Celum C, Katabira E, Mugo NR, Baeten JM; Partners Demonstration Project Team.

J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):41-45. doi: 10.1097/QAI.0000000000001561.

25.

A cross-sectional analysis of Trichomonas vaginalis infection among heterosexual HIV-1 serodiscordant African couples.

Bochner AF, Baeten JM, Rustagi AS, Nakku-Joloba E, Lingappa JR, Mugo NR, Bukusi EA, Kapiga S, Delany-Moretlwe S, Celum C, Barnabas RV; Partners in Prevention HSV/HIV Transmission Study and Partners PrEP Study Teams.

Sex Transm Infect. 2017 Nov;93(7):520-529. doi: 10.1136/sextrans-2016-053034. Epub 2017 Apr 4.

PMID:
28377421
26.

Costs of integrating cervical cancer screening at an HIV clinic in Kenya.

Vodicka EL, Babigumira JB, Mann MR, Kosgei RJ, Lee F, Mugo NR, Okech TC, Sakr SR, Garrison LP Jr, Chung MH.

Int J Gynaecol Obstet. 2017 Feb;136(2):220-228. doi: 10.1002/ijgo.12025. Epub 2016 Nov 21.

PMID:
28099724
27.

Effect of Pregnancy on Response to Antiretroviral Therapy in HIV-Infected African Women.

Kourtis AP, Wiener J, King CC, Heffron R, Mugo NR, Nanda K, Pyra M, Donnell D, Celum C, Lingappa JR, Baeten JM; Partners in Prevention HSVHIV Transmission Study and Partners PrEP Study Teams.

J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):38-43.

28.

PrEP implementation research in Africa: what is new?

Cowan FM, Delany-Moretlwe S, Sanders EJ, Mugo NR, Guedou FA, Alary M, Behanzin L, Mugurungi O, Bekker LG.

J Int AIDS Soc. 2016 Oct 18;19(7(Suppl 6)):21101. doi: 10.7448/IAS.19.7.21101. eCollection 2016.

29.

Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.

Mugwanya KK, Hendrix CW, Mugo NR, Marzinke M, Katabira ET, Ngure K, Semiyaga NB, John-Stewart G, Muwonge TR, Muthuri G, Stergachis A, Celum CL, Baeten JM.

PLoS Med. 2016 Sep 27;13(9):e1002132. doi: 10.1371/journal.pmed.1002132. eCollection 2016 Sep.

30.

Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda.

Baeten JM, Heffron R, Kidoguchi L, Mugo NR, Katabira E, Bukusi EA, Asiimwe S, Haberer JE, Morton J, Ngure K, Bulya N, Odoyo J, Tindimwebwa E, Hendrix C, Marzinke MA, Ware NC, Wyatt MA, Morrison S, Haugen H, Mujugira A, Donnell D, Celum C; Partners Demonstration Project Team.

PLoS Med. 2016 Aug 23;13(8):e1002099. doi: 10.1371/journal.pmed.1002099. eCollection 2016 Aug.

31.

Gendered differences in the perceived risks and benefits of oral PrEP among HIV-serodiscordant couples in Kenya.

Carroll JJ, Ngure K, Heffron R, Curran K, Mugo NR, Baeten JM.

AIDS Care. 2016 Aug;28(8):1000-6. doi: 10.1080/09540121.2015.1131972. Epub 2016 Jan 11.

32.

Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples.

Magaret AS, Mujugira A, Hughes JP, Lingappa J, Bukusi EA, DeBruyn G, Delany-Moretlwe S, Fife KH, Gray GE, Kapiga S, Karita E, Mugo NR, Rees H, Ronald A, Vwalika B, Were E, Celum C, Wald A; Partners in Prevention HSV/HIV Transmission Study Team.

Clin Infect Dis. 2016 Feb 15;62(4):456-61. doi: 10.1093/cid/civ908. Epub 2015 Nov 17.

33.

The preexposure prophylaxis revolution; from clinical trials to programmatic implementation.

Mugo NR, Ngure K, Kiragu M, Irungu E, Kilonzo N.

Curr Opin HIV AIDS. 2016 Jan;11(1):80-6. doi: 10.1097/COH.0000000000000224. Review.

34.

Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy.

Pyra M, Heffron R, Mugo NR, Nanda K, Thomas KK, Celum C, Kourtis AP, Were E, Rees H, Bukusi E, Baeten JM; Partners in Prevention HSVHIV Transmission Study and Partners PrEP Study Teams.

AIDS. 2015 Nov;29(17):2353-9. doi: 10.1097/QAD.0000000000000827.

35.

Methylation Levels of CADM1, MAL, and MIR124-2 in Cervical Scrapes for Triage of HIV-Infected, High-Risk HPV-Positive Women in Kenya.

De Vuyst H, Franceschi S, Plummer M, Mugo NR, Sakr SR, Meijer CJ, Heideman DA, Tenet V, Snijders PJ, Hesselink AT, Chung MH.

J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):311-8. doi: 10.1097/QAI.0000000000000744.

PMID:
26473640
36.

Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women.

Thomson KA, Baeten JM, Mugo NR, Bekker LG, Celum CL, Heffron R.

Curr Opin HIV AIDS. 2016 Jan;11(1):18-26. doi: 10.1097/COH.0000000000000207. Review.

37.

Acyclovir Prophylaxis Reduces the Incidence of Herpes Zoster Among HIV-Infected Individuals: Results of a Randomized Clinical Trial.

Barnabas RV, Baeten JM, Lingappa JR, Thomas KK, Hughes JP, Mugo NR, Delany-Moretlwe S, Gray G, Rees H, Mujugira A, Ronald A, Stevens W, Kapiga S, Wald A, Celum C; Partners in Prevention HSV/HIV Transmission Study Team.

J Infect Dis. 2016 Feb 15;213(4):551-5. doi: 10.1093/infdis/jiv318. Epub 2015 Jun 8.

38.

Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.

Lehman DA, Baeten JM, McCoy CO, Weis JF, Peterson D, Mbara G, Donnell D, Thomas KK, Hendrix CW, Marzinke MA, Frenkel L, Ndase P, Mugo NR, Celum C, Overbaugh J, Matsen FA; Partners PrEP Study Team.

J Infect Dis. 2015 Apr 15;211(8):1211-8. doi: 10.1093/infdis/jiu677. Epub 2015 Jan 13.

39.

Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.

Mugwanya KK, Wyatt C, Celum C, Donnell D, Mugo NR, Tappero J, Kiarie J, Ronald A, Baeten JM; Partners PrEP Study Team.

JAMA Intern Med. 2015 Feb;175(2):246-54. doi: 10.1001/jamainternmed.2014.6786.

40.

Residual disease and HPV persistence after cryotherapy for cervical intraepithelial neoplasia grade 2/3 in HIV-positive women in Kenya.

De Vuyst H, Mugo NR, Franceschi S, McKenzie K, Tenet V, Njoroge J, Rana FS, Sakr SR, Snijders PJ, Chung MH.

PLoS One. 2014 Oct 24;9(10):e111037. doi: 10.1371/journal.pone.0111037. eCollection 2014.

41.

Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.

Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Coombs RW, Hendrix C, Marzinke MA, Frenkel L, Haberer JE, Bangsberg D, Celum C; Partners PrEP Study Team.

Lancet Infect Dis. 2014 Nov;14(11):1055-1064. doi: 10.1016/S1473-3099(14)70937-5. Epub 2014 Oct 7.

42.

Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men.

Were EO, Heffron R, Mugo NR, Celum C, Mujugira A, Bukusi EA, Baeten JM; Partners PrEP Study Team.

AIDS. 2014 Aug 24;28(13):1977-82. doi: 10.1097/QAD.0000000000000313.

43.

High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.

Matthews LT, Heffron R, Mugo NR, Cohen CR, Hendrix CW, Celum C, Bangsberg DR, Baeten JM; Partners PrEP Study Team.

J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):91-7. doi: 10.1097/QAI.0000000000000246.

44.

Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.

Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, Wangisi J, Were E, Heffron R, Matthews LT, Morrison S, Ngure K, Baeten JM; Partners PrEP Study Team.

JAMA. 2014 Jul 23-30;312(4):362-71. doi: 10.1001/jama.2014.8735.

45.

Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception.

Murnane PM, Heffron R, Ronald A, Bukusi EA, Donnell D, Mugo NR, Were E, Mujugira A, Kiarie J, Celum C, Baeten JM; Partners PrEP Study Team.

AIDS. 2014 Jul 31;28(12):1825-30. doi: 10.1097/QAD.0000000000000290.

46.

Variants in host viral replication cycle genes are associated with heterosexual HIV-1 acquisition in Africans.

Bigham AW, Mackelprang RD, Celum C, De Bruyn G, Beima-Sofie K, John-Stewart G, Ronald A, Mugo NR, Buckingham K, Bamshad MJ, Mullins JI, McElrath MJ, Lingappa JR.

J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):127-34. doi: 10.1097/QAI.0000000000000113.

47.

Unreported antiretroviral use by HIV-1-infected participants enrolling in a prospective research study.

Kahle EM, Kashuba A, Baeten JM, Fife KH, Celum C, Mujugira A, Essex M, De Bruyn G, Wald A, Donnell D, John-Stewart G, Delany-Moretlwe S, Mugo NR, Farquhar C, Lingappa JR; Partners in Prevention HSVHIV Transmission Study Team.

J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):e90-4. doi: 10.1097/QAI.0b013e3182a2db02. No abstract available.

48.

'If I am given antiretrovirals I will think I am nearing the grave': Kenyan HIV serodiscordant couples' attitudes regarding early initiation of antiretroviral therapy.

Curran K, Ngure K, Shell-Duncan B, Vusha S, Mugo NR, Heffron R, Celum C, Baeten JM.

AIDS. 2014 Jan 14;28(2):227-33. doi: 10.1097/QAD.0000000000000025.

49.

Clustering patterns of human papillomavirus infections among HIV-positive women in Kenya.

Vaccarella S, De Vuyst H, Mugo NR, Sakr SR, Plummer M, Heideman DA, Franceschi S, Chung M.

Infect Agent Cancer. 2013 Dec 19;8(1):50. doi: 10.1186/1750-9378-8-50.

50.

Prevalence and incidence of cervical intra-epithelial neoplasia among female sex workers in Korogocho, Kenya.

Njagi SK, Mugo NR, Reid AJ, Satyanarayana S, Tayler-Smith K, Kizito W, Kwatampora J, Waweru W, Kimani J, Smith JS.

Public Health Action. 2013 Dec 21;3(4):271-5. doi: 10.5588/pha.13.0057.

Supplemental Content

Support Center